Market revenue in 2023 | USD 3,436.3 million |
Market revenue in 2030 | USD 6,085.5 million |
Growth rate | 8.5% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67% in 2023. Horizon Databook has segmented the North America large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
North America is one of the major contributors of large molecule drug substance CDMO market. This region is home to a large number of biopharmaceutical companies that outsource part of their manufacturing activities to CMOs and CDMOs, thereby contributing to market growth.
Increase in cost of developing large molecules is a major challenge, which has encouraged biopharmaceutical companies in North America to outsource few processes to CDMOs with expertise in the domain.
Moreover, global biopharmaceutical companies prefer CMOs based in North America to easily access the market. It is characterized by presence of several established biopharmaceuticals, pharmaceutical, and contract research organizations.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America large molecule drug substance cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into North America large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account